Aclaris Therapeutics — October 27, 2026 Earnings Summary

Aclaris Therapeutics announced positive primary analysis results from Phase 1b proof-of-concept trials for its bispecific antibody ATI-052 in patients with atopic dermatitis and asthma. In the atopic dermatitis trial, patients receiving ATI-052 demonstrated a 45% placebo-adjusted reduction in EASI scores and significant itch relief within the first week, alongside a favorable safety profile with no observed conjunctivitis. The asthma trial showed that a single dose of ATI-052 rapidly reduced fractional exhaled nitric oxide by 59% and improved lung function within 15 days. Based on these results, Aclaris intends to prioritize the development of ATI-052 in eosinophilic esophagitis, with a Phase 2b trial expected to begin early next year.